Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM-XAN002
- Development stage
- Preclinical
- Lead developer
- Xantho Biotechnology Co., LTD
- Administration
- Topical
01
Overview
GM-XAN002 is a botanical drug candidate developed by Xantho Biotechnology for the treatment of pressure ulcers. Formulated as a topical ointment, it is designed to facilitate wound healing by reducing inflammation, promoting epidermal regeneration, stimulating granulation tissue formation, and enhancing angiogenesis. Preclinical studies in mouse models of pressure ulcers have demonstrated its potential to improve healing outcomes. The drug is part of a broader pipeline of botanical treatments aimed at providing alternatives to topical steroids and immunosuppressants with lower side-effect profiles. It is currently in the IND-enabling stage of development.
Beyond the preview
Go deeper on GM-XAN002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM-XAN002.